Literature DB >> 12036945

Inactivation of E2f1 enhances tumorigenesis in a Myc transgenic model.

Robert J Rounbehler1, Pamela M Rogers, Claudio J Conti, David G Johnson.   

Abstract

Previous studies have demonstrated both oncogenic and tumor suppressive properties for the E2F1 transcription factor. In this study, E2f1-null mice were crossed with transgenic mice expressing Myc under the control of an epithelial-specific keratin 5 promoter to determine whether the absence of E2F1 would modulate the oncogenic activity of Myc. Inactivation of E2f1 was found to significantly accelerate tumor development in keratin 5 Myc transgenic mice. Acceleration of tumorigenesis occurred despite the fact that apoptosis levels were increased in transgenic tissue and tumors null for E2f1, whereas Myc-induced proliferation was unaffected by the status of E2f1. These findings provide new insight into the tumor suppressive activity of E2F1 and identify for the first time a specific oncogenic alteration that cooperates with the loss of E2F1 in tumorigenesis.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12036945

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  16 in total

1.  E2F1 localizes to sites of UV-induced DNA damage to enhance nucleotide excision repair.

Authors:  Ruifeng Guo; Jie Chen; Feng Zhu; Anup K Biswas; Thomas R Berton; David L Mitchell; David G Johnson
Journal:  J Biol Chem       Date:  2010-04-22       Impact factor: 5.157

2.  ATM promotes apoptosis and suppresses tumorigenesis in response to Myc.

Authors:  Raju V Pusapati; Robert J Rounbehler; SungKi Hong; John T Powers; Mingshan Yan; Kaoru Kiguchi; Mark J McArthur; Paul K Wong; David G Johnson
Journal:  Proc Natl Acad Sci U S A       Date:  2006-01-23       Impact factor: 11.205

3.  E2F1 promotes the recruitment of DNA repair factors to sites of DNA double-strand breaks.

Authors:  Jie Chen; Feng Zhu; Regina L Weaks; Anup K Biswas; Ruifeng Guo; Yanjie Li; David G Johnson
Journal:  Cell Cycle       Date:  2011-04-15       Impact factor: 4.534

4.  Skp2 is necessary for Myc-induced keratinocyte proliferation but dispensable for Myc oncogenic activity in the oral epithelium.

Authors:  Christopher Sistrunk; Everardo Macias; Keiichi Nakayama; Yongbaek Kim; Marcelo L Rodriguez-Puebla
Journal:  Am J Pathol       Date:  2011-06       Impact factor: 4.307

5.  Viral-mediated noisy gene expression reveals biphasic E2f1 response to MYC.

Authors:  Jeffrey V Wong; Guang Yao; Joseph R Nevins; Lingchong You
Journal:  Mol Cell       Date:  2011-02-04       Impact factor: 17.970

6.  Lack of cyclin-dependent kinase 4 inhibits c-myc tumorigenic activities in epithelial tissues.

Authors:  Paula L Miliani de Marval; Everardo Macias; Robert Rounbehler; Piotr Sicinski; Hiroaki Kiyokawa; David G Johnson; Claudio J Conti; Marcelo L Rodriguez-Puebla
Journal:  Mol Cell Biol       Date:  2004-09       Impact factor: 4.272

7.  E2F1 responds to ultraviolet radiation by directly stimulating DNA repair and suppressing carcinogenesis.

Authors:  Anup Kumar Biswas; David L Mitchell; David G Johnson
Journal:  Cancer Res       Date:  2014-04-16       Impact factor: 12.701

8.  Frap, FKBP12 rapamycin-associated protein, is a candidate gene for the plasmacytoma resistance locus Pctr2 and can act as a tumor suppressor gene.

Authors:  Valery Bliskovsky; Edward S Ramsay; John Scott; Wendy DuBois; Wei Shi; Shuling Zhang; Xiaolan Qian; Douglas R Lowy; Beverly A Mock
Journal:  Proc Natl Acad Sci U S A       Date:  2003-11-21       Impact factor: 11.205

Review 9.  Targeting snoRNAs as an emerging method of therapeutic development for cancer.

Authors:  Di Zhang; Juan Zhou; Jie Gao; Ri-Ying Wu; Ying-Long Huang; Qin-Wen Jin; Jian-Si Chen; Wei-Zhong Tang; Lin-Hai Yan
Journal:  Am J Cancer Res       Date:  2019-08-01       Impact factor: 6.166

10.  E2F2 suppresses Myc-induced proliferation and tumorigenesis.

Authors:  Raju V Pusapati; Regina L Weaks; Robert J Rounbehler; Mark J McArthur; David G Johnson
Journal:  Mol Carcinog       Date:  2010-02       Impact factor: 4.784

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.